Transforming Clinical Trials with Cutting-Edge ML
All Case Studies
Rescuing a Failed Trial: PhaseV Response Optimizer Identifies Key Responders to Investigational Oral Insulin Treatment
Oramed’s Phase III oral insulin trial failed to meet its primary endpoint. PhaseV’s Response Optimizer identified responsive patient subgroups, leading to a targeted Phase III re-trial.
PhaseV’s Response Optimizer identified responsive patient subgroups.
Accelerating SLE Trials: Early Derived Endpoint Reduces Sample Size & Enhances Trial Efficiency
Clinical trials in SLE face challenges due to disease heterogeneity and long follow-up periods. PhaseV’s ML analysis identified early response signals, enabling adaptive trial design and efficiency.
ML early endpoints optimized trials and improved success.
Optimizing a Phase III Trial for Sample Size
PhaseV optimized a biotech company's Phase III trial, reducing sample size while maintaining efficacy and meeting objectives through simulations.
Optimized trial design reduced sample size by 10-15%.
Enhancing Phase II Success with Subgroup Enrichment Strategy
PhaseV’s simulations identified an optimal subgroup enrichment strategy for a Phase II trial, improving statistical power and efficiency, leading to a more targeted study design.
Subgroup enrichment improved statistical power and efficiency.